Valuation: Roche Holding AG

Market Cap 284B 351B 303B 259B 487B 33,580B 494B 3,334B 1,307B 16,823B 1,319B 1,290B 55,962B P/E 2026 *
19.8x
P/E 2027 * 17.6x
Enterprise Value 295B 365B 315B 269B 506B 34,863B 513B 3,462B 1,357B 17,466B 1,369B 1,339B 58,100B EV / Sales 2026 *
4.71x
EV / Sales 2027 * 4.41x
Free-Float
88.78%
Yield 2026 *
2.81%
Yield 2027 * 2.87%
1 day+0.47%
1 week-2.51%
Current month+1.67%
1 month+8.32%
3 months+10.69%
6 months-3.13%
Current year+8.77%
1 week 358.2
Extreme 358.2
372.8
1 month 332.2
Extreme 332.2
378.8
Current year 301.2
Extreme 301.2
383
1 year 264.6
Extreme 264.6
383
3 years 229.4
Extreme 229.4
383
5 years 229.4
Extreme 229.4
439.2
10 years 209.4
Extreme 209.4
439.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-2.51% - - 351B
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+1.05%-2.66%+40.27%+40.80% 351B
+0.58%-1.49%+23.71%+38.70% 290B
+0.46%-2.03%-1.14%+8.88% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.21%-5.18%-16.17%-53.44% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.49%-1.44%+27.10%+45.91% 401.39B
Weighted average by Cap. +0.48%-1.87%+39.42%+64.42%

Financials

2026 *2027 *
Net sales 62.64B 77.35B 66.77B 57.06B 107B 7,395B 109B 734B 288B 3,705B 290B 284B 12,325B 65.47B 80.84B 69.79B 59.63B 112B 7,729B 114B 767B 301B 3,872B 303B 297B 12,881B
Net income 14.51B 17.91B 15.46B 13.21B 24.84B 1,713B 25.19B 170B 66.64B 858B 67.24B 65.79B 2,854B 16.33B 20.17B 17.41B 14.88B 27.97B 1,928B 28.36B 191B 75.03B 966B 75.71B 74.07B 3,213B
Net Debt 10.87B 13.42B 11.58B 9.9B 18.61B 1,283B 18.87B 127B 49.92B 643B 50.37B 49.28B 2,138B 4.02B 4.96B 4.28B 3.66B 6.88B 475B 6.98B 47.12B 18.46B 238B 18.63B 18.23B 791B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
18/08/26 CHF 364.60 +0.50% 1,682
17/08/26 CHF 362.80 +0.28% 18,937
14/08/26 CHF 361.80 -1.63% 17,569
13/08/26 CHF 367.80 -0.70% 15,225
12/08/26 CHF 370.40 -0.96% 22,496
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
356.10CHF
Average target price
370.31CHF
Spread / Average Target
+3.99%

Quarterly revenue - Rate of surprise